News

The study results confirmed its primary aim to show bioequivalence of an optimized formulation of HyNap-Dasa compared to Sprycel. The data will be instrumental in the design of

The British pharma giant is seeking approval for mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment for reducing exacerbations in patients with COPD guided by blood

In this regard, the two firms have signed a global clinical collaboration agreement to assess the safety, tolerability and preliminary efficacy of their drugs combination. Lifirafenib is a

GSK recently revealed its target of generating annual cost savings of £400m by 2021 by implementing the restructuring program across the group. The restructuring program was taken up

Commonly referred to as superbugs, the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) collectively comprise the leading cause of hospital-acquired infections

Since the initiative was announced in January 2018, more than 120 health organizations representing about a third of the nation’s hospitals have contacted Civica Rx and expressed a

Filgotinib, an investigational and selective JAK1 inhibitor, has achieved its primary efficacy endpoint in adults with moderately to severely active AS in the phase 2 Tortuga study. AS

Imprime PGG is an innate immune trigger that activates anti-cancer T cells.  Durvalumab is a human monocolonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and

Proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for